Do you know the options available to prevent RSV in infants?
RSV Prevention Options for Infants
The Indirect Impact of RSV
RSV, or respiratory syncytial virus, is a common, highly contagious seasonal virus that affects 97% of children by the age of 2. Yet despite RSV being common among young children, most parents know little about it.
Vaccines and Preventive Monoclonal Antibodies
Vaccines and preventive monoclonal antibodies are two different types of immunization. While they function differently, they both serve the same purpose: protecting people from serious illnesses and diseases.
The Burden of RSV: Impacting All Families
Respiratory syncytial virus places a heavy burden on infants, young children, their families and the health care system. Also known as RSV, this virus can impact children and families for months, years or even their entire lives.
And it doesn’t discriminate.
Monoclonal Antibodies Inclusion in the Vaccines for Children Program
By warding off diseases like influenza and pertussis, immunizations play a critical role in infant and early childhood health. Immunizations protect infants from life-threatening diseases, which can lead to both hospitalization and longterm complications.
Infant Health Matters: RSV
A conversation with Donald M. Null, MD.
Q: What is RSV?
Respiratory syncytial virus is a seasonal virus that causes an infection of the lungs. RSV is the leading cause of hospitalization in children younger than one year old.
In Conversation: A Nurse Practitioner Discusses COVID-19 and Infant Health
How are infants affected by COVID-19?
Dr. S: NICUs are starting to see babies born to COVID-positive mothers. Some of these babies may also test positive. The mothers are sick, but many times the babies have no symptoms. These babies still require isolation and one-on-one staffing. No visitors. Generally you see infants and children contracting COVID less frequently and not having as difficult a time with it as older adults do. One theory says that may be because of all the vaccinations young children receive. Their immune systems are bolstered.
National Statistics: Respiratory Syncytial Virus
A national data supplier provided palivizumab claims for Medicaid and commercial health plans across the nation from January 2019 through December 2019.
Health plans deny 40% of palivizumab prescriptions for premature infants born between 29 and 36 weeks gestation.
One in every four prescriptions is denied for infants who should qualify for coverage under standard insurance policies.